This report was first published by Endpoints News. To see the original version, click here
ImmunityBio’s off-the-shelf cell therapy has shown early promise in a small trial in a rare form of lymphoma.
The ongoing Phase 1 study, named QUILT-106, has so far signed up four patients with Waldenström non-Hodgkin lymphoma, a B cell cancer. ImmunityBio’s program is an allogeneic CD19 chimeric antigen receptor natural killer (CAR-NK) cell therapy, and in the trial, it was combined with Biogen and Roche’s CD20-targeting antibody Rituxan.
您已阅读19%（532字），剩余81%（2211字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。